Novel Enteric Dialysis(TM) technology

Kibow Biotech, Inc. will be introducing the concept of Enteric Dialysis(TM) at the American Society of Nephrology (ASN) Renal Week 2008, being held at PA Convention Center in Philadelphia, November 4-9.

Dr. Natarajan Ranganathan, the key founder, VP (R&D) and interim CEO stated, "We are pleased and honored to present the latest developments concerning our patented and proprietary Enteric Dialysis™ technology to the international nephrology community at Renal Week 2008. We are extremely grateful to our scientific advisory board members who have guided and encouraged our R&D work over the past 10 years, supporting us in our belief that the elegant simplicity, cost savings, convenience and effectiveness of our probiotic-based technology will have profound clinical implications for the management of CKF in both advanced and developing countries”.

Kibow Biotech Inc., with headquarters in Newtown Square, Pennsylvania, will also be exhibiting Kibow Biotics(R), the company's core product, at the ASN meeting. Presented as an enteric coated gel capsule, Kibow Biotics(R) is an orally consumable formulation, intended to help improve the quality of life for chronic kidney failure (CKF) patients by possibly delaying the progression of their condition into End-Stage Renal Disease (ESRD stage V). Having a high affinity for uremic toxins, Kibow Biotics(R) works on the principal of Enteric Dialysis(TM) to remove the accumulated uremic toxins diffusing from the blood into the bowel.

Kibow Biotech is currently conducting a pilot- scale, double-blind, randomized, cross-over human clinical trial for a period of six months at 6 study sites in the USA (2 sites), Canada, Mexico, Argentina and Nigeria (www.clinicaltrials.gov - identifier NCT00760162). Kibow Biotics(R) is scheduled to be available for marketing and sale in the USA by early 2009 upon successful completion of the on-going multisite clinical trials in the aforementioned countries. Licensed to Vétoquinol, S.A., the veterinary application of Kibow's technology and its patented probiotic product formulation (trade named AZODYL™) for cats and dogs with moderate to severe kidney failure has been successfully sold in the US and in Canada since 2006.

About Kibow Biotics(R)
Kibow Biotics(R) is an orally administered patented formulation of specially developed strains of naturally occurring bacteria or microbes which metabolize targeted uremic toxins in the gut and consume them as nutrients for their own growth. Clinical evidence shows that it may reduce bloodstream concentrations of urea, uric acid, creatinine, indoles and phenols, nitrosamines and related uremic metabolites. Kibow Biotics(R) also promote maintenance of normal healthy gut flora.

About Kibow Biotech, Inc.
Kibow Biotech, Inc. is an eleven-year-old, developing-stage biotechnology company having its R&D operations in Newtown Square, PA, USA. The company is dedicated to finding a simple, convenient and cost-effective worldwide solution for patients suffering from chronic kidney failure. The company's first generation product called Kibow Biotics(R); an orally consumable, enteric coated gel cap product formulation is composed of food grade microbes ("Probiotics") which metabolize the uremic toxins diffusing into the bowel as a consequence of increased levels of these toxins in the blood. It is targeted to help augment or maintain kidney function for Chronic Kidney Failure (CKF) patients (pre-dialysis) and has the potential to reduce the duration and/or frequency of dialysis for End Stage Renal Disease (ESRD) patients.

For additional information, contact:
Kibow Biotech, Inc.
4629 West Chester Pike
Newtown Business Center
Newtown Square, PA 19073 USA
Tel: (610) 353 5130
Fax: (610) 353 5110
info@kibowbiotech.com
www.kibow.com

Source : http://www.einnews.com/pr-news/10529-novel-enteric-dialysis-tm-technology-to-be-introduced-by-kibow-biotech-at-asn-2008